The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction.
D000818:Animals; D016255:Anistreplase; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010958:Plasminogen / Q000627:therapeutic use*; D011897:Random Allocation; D012008:Recurrence; D013300:Streptokinase / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase